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Bronchiectasis is a chronic suppurative pulmonary disorder generally 
defined as irreversible dilatation of the central and peripheral 
airways.[1] It is associated with periodic infectious exacerbations, 
which are defined as an increase in the severity and wet character of 
the cough.[2] There is chronic bacterial colonisation of the bronchi, 
and an increase in inflammatory cells and mediators in the bronchial 
mucosa and bronchial walls.[3] This leads to a vicious cycle of 
recurrent chest infections and chronic inflammatory changes leading 
to the eventual destruction of the structural elements within the 
bronchial wall.
Irrespective of the cause of the bronchiectasis, the structural damage 
to the airways predisposes the patient to repeated lower respiratory tract 
infections that can cause further damage to the lungs.[4] To limit damage 
to the airways and lung parenchyma, acute infective exacerbations 
should be treated early and aggressively with antimicrobials. Knowing 
which bacteria are found in the airways of patients with bronchiectasis 
is important in defining empirical antibiotic guidelines for the 
management of acute infective exacerbations.
The airway-colonising bacteria resulting in acute infective 
exacerbations in patients with cystic fibrosis (CF) bronchiectasis have 
been extensively described. Colonisation takes place from an early 
age, with Staphylococcus aureus and Haemophilus influenzae being 
common, followed by Pseudomonas aeruginosa, which becomes 
increasingly prominent in older patients.[5]
Studies in adult patients with non-CF bronchiectasis have shown 
that H. influenzae, P. aeruginosa and Streptococcus pneumoniae are 
the most common organisms isolated.[6] Adult patients with CF 
bronchiectasis are more likely to be colonised with P. aeruginosa than 
adults with non-CF bronchiectasis.[7]
An increasing number of studies have described the organisms 
colonising the airways in paediatric non-CF bronchiectasis.[8] The 
bacteria most commonly found to be colonising the airways of HIV-
uninfected children with non-CF bronchiectasis are H. influenzae, 
S. pneumoniae, Moraxella catarrhalis and S. aureus. Most of these 
studies are from developed countries where there have been no 
reports on bacteria colonising the airways of HIV-infected patients. 
In developing countries, Ferrand et al.[9] described the organisms 
found in the airways of adolescents with vertically transmitted HIV in 
Zimbabwe. A positive bacterial/fungal sputum culture was reported 
in 18 of 54 patients with cough, H. influenzae (n=6), S. aureus (n=5), 
M. catarrhalis (n=5), P. aeruginosa (n=3) and S. pneumoniae (n=2) 
being the most commonly reported bacteria. Masekela et al.[10] 
studied a cohort of 35 HIV-infected children with bronchiectasis in 
South Africa (SA), and found that the most common organisms were 
H. influenzae and H. parainfluenzae, which accounted for 49% of 
organisms cultured.
It is not clear whether bacterial colonisation of the airways in non-
CF bronchiectasis differs between HIV-infected and HIV-uninfected 
children. Having this information is vital when choosing which 
antimicrobials to use during an acute exacerbation.
Objective
To determine the bacteria isolated from children with non-CF 
bronchiectasis in a setting with a high prevalence of HIV.
Methods
Study design
This was a retrospective observational study.
Study setting
The study setting was Chris Hani Baragwanath Academic Hospi-
tal (CHBAH), a tertiary public government hospital in Soweto, 
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Johannes burg, SA. All paediatric patients with suspected bronchiec-
tasis are referred to a paediatric pulmonologist or to the paediatric 
pulmonology clinic. Diagnosis of bronchiectasis is made on clinical 
assessment and confirmed with a chest radiograph or a computed 
tomography scan of the chest.
Study population
The study population comprised children aged <16 years attending 
the paediatric pulmonology clinic or admitted to CHBAH with a 
diagnosis of non-CF bronchiectasis from 1 April 2011 to 31 March 
2013. Children with bronchiectasis in whom CF had been confirmed 
were excluded from the study.
Management of patients with bronchiectasis at CHBAH
Airway samples were taken for bacterial surveillance from all patients 
at the time of diagnosis of bronchiectasis. Samples were then taken 
on a regular basis, approximately every 3 months, and during every 
acute exacerbation or admission. Airway samples were collected by 
spontaneous expectoration, sputum induction, tracheal aspiration 
(TA) or bronchoalveolar lavage (BAL) during bronchoscopy. All 
samples were sent to the National Health Laboratory Service (NHLS) 
at CHBAH.
All samples were first examined with the Gram staining method 
and designated Gram-positive or negative. Qualitative tests were 
performed to determine whether the samples taken were representative 
of the upper or lower respiratory tract by assessing the number of 
polymorphonuclear and squamous epithelium cells per low-power 
field (10× magnification). Only samples from the lower airways were 
included in the analysis. Samples were inoculated on 5% horse blood 
agar incubated in CO2 at 35oC, MacConkey agar incubated aerobically 
at 35oC, and bacitracin heated blood agar incubated in CO2 at 35oC. 
All inoculated media were read after 24 and 48 hours. The bacterial 
organism was identified if any of the plates yielded positive growth. 
Positive cultures were further quantified to establish the density of the 
bacterial growth in the culture. Culture density was reported as <10 
colony-forming units (CFU), 10 - 99 CFU or ≥100 CFU on the initial 
inoculum. Specific anaero bic cultures were not routinely performed 
owing to the technical difficulties and low yield of this test.
HIV testing was routinely performed on all patients admitted to the 
paediatric wards according to National Department of Health guidelines. 
HIV serological testing using the enzyme-linked immunosorbent assay 
(ELISA) was carried out for children >18 months of age, with a 
confirmatory serological test (HIV combination Ab/P24 Ag) performed 
if the ELISA was reactive. HIV polymerase chain reaction (qualitative) 
testing was used for children aged <18 months.
Data collection
Data were collected from the patients’ paediatric pulmonology files 
and from the computerised NHLS results database. The following 
data were collected: patient demographics, past medical history, 
radiological features, and laboratory findings including HIV status, 
CD4 count, viral load, number and type of sputum samples collected, 
sputum microscopy and sputum culture results.
Data analysis
All samples collected from patients were included in the analysis, 
including multiple samples from the same patient. Data were entered 
onto an Excel spreadsheet, version 2010 (Microsoft, USA). Statistical 
analysis was performed using Statistica version 12 (StatSoft, USA). 
Data were summarised using means and standard deviations 
(SDs) for continuous variables with normal distribution; medians, 
interquartile ranges (IQRs) and ranges for continuous data without 
normal distribution; and proportions and percentages for categorical 
variables. Comparisons between HIV-infected and uninfected 
patients with bronchiectasis were performed using Student’s t-test 
for continuous variables with normal distribution and the Mann-
Whitney U-test for those without normal distribution. The χ2 test or 
Fisher’s exact test was used for categorical variables. Differences were 
considered to be statistically significant when the p-value was <0.05.
Ethics approval
Permission to perform the study was obtained from the Hospital 
Protocol Review Committee and the Human Research Ethics 
Committee of the University of the Witwatersrand (ref. no. M130415).
Results
Sixty-six patients with non-CF bronchiectasis had airway samples 
analysed at CHBAH from April 2011 to March 2013 (Table 1). Most 
patients were of black African descent (96.9%), and 78.8% of patients 
were HIV-infected. The median CD4 percentage and viral load in the 
HIV-infected patients were 17.2% (IQR 4.7 - 28.5) and 18 422 copies/
mL (IQR 0.0 - 166 475), respectively. Thirty-seven HIV-infected 
patients (71.1%) were known to be on antiretrovirals (ARVs), and 
in 30 patients the duration of ARV therapy was known (median 
duration 60 months, IQR 12 - 84). There was no statistically significant 
difference between the HIV-infected and uninfected patients with 
regard to gender (54.5% female). HIV-infected patients were older 
at presentation (median age 11.4 years, IQR 7.7 - 12.5) than HIV-
uninfected children (median age 7.1 years, IQR 6.0 - 7.8) (p=0.002).
Sixty-three percent of patients had bilateral bronchiectasis, 
with the mean (SD) number of lung lobes affected being 3 (1.4). 
There was no difference in this regard between HIV-infected and 
uninfected patients. The underlying causes of the bronchiectasis 
in the HIV-uninfected group were post-infectious (n=5), post-
tuberculosis infection (n=1), primary immunodeficiency (n=3), non-
HIV acquired immunodeficiency (malignancy and chemotherapy) 
(n=1), aspiration syndrome (n=3) and unknown (n=1). A total 
of 134 samples were collected from the 66 patients (Table 2). The 
Table 1. Demographic characteristics of the study patients according to HIV status
Characteristics All patients (N=66) HIV+ (N=52) HIV– (N=14) p-value, HIV+ v. HIV–
Age (yr)
Median (IQR) 9.1 (7.2 - 12.1) 11.4 (7.7 - 12.5) 7.1 (6.0 - 7.8) 0.002
1 - 5, n (%) 5 (7.5) 3 (5.7) 2 (14.3)
>5 - 16, n (%) 61 (92.4) 49 (94.2) 12 (85.7)
Gender, n (%)
Male 30 (45.5) 25 (48.1) 5 (35.7) 0.303
Female 36 (54.5) 27 (51.9) 9 (64.2)
HIV+ = HIV-infected; HIV– = HIV-uninfected.
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median number of samples collected per patient was 2 (range 1 - 7). 
Thirty-three patients (50.0%) had 1 sample collected, 17 (25.8%) had 
2 samples collected and 16 (24.2%) had ≥3 samples collected. There 
was no statistical difference between the number of samples collected 
from HIV-infected and uninfected patients. Most specimens (81.3%) 
were collected as expectorated or induced sputum; only 25 were BAL 
or TA specimens. More HIV-uninfected patients than HIV-infected 
patients had BAL specimens collected (p<0.05) (Table 2).
There was no statistical difference between HIV-infected and 
HIV-uninfected patients when comparing the number of positive 
and negative bacterial cultures, bacteria cultured per sample or the 
density of individual bacterial culture colonies (Table 2).
The main bacteria cultured were H. influenzae, S. pneumoniae, 
M. catarrhalis, S. aureus, Pseudomonas species, Klebsiella species and 
H. parainfluenzae (Fig. 1).
The types and numbers of Gram-negative and Gram-positive 
bacteria cultured in all samples are shown in Table 3.
When comparing samples from HIV-infected and uninfected 
patients with regard to bacteria cultured, there were no statistically 
significant differences except that Pseudomonas species were more 
likely to be cultured from HIV-uninfected patient samples (Table 3). 
When reanalysing the data on an individual patient basis, it was 
found that one patient had seven samples positive for P. aeruginosa, 
and there was no statistical difference between HIV-infected and 
uninfected patients in frequency of P. aeruginosa in airway samples.
Thirty-three patients (50.0%) had two or more samples collected, 
and of these 28 (84.8%) cultured at least one bacterium in two or 
more samples. Of these, 20 (71.4%) had recurrence of the same 
organism in subsequent samples. When H. influenzae was cultured 
in a sample from an individual patient, there was a 69.5% chance that 
it would be cultured in subsequent samples from the same patient. 
There was a 63.6% chance of this occurring for S. pneumoniae, a 
50.0% chance for M. catarrhalis and a 25.0% chance for S. aureus. 
H. parainfluenzae was not cultured in subsequent sputum samples for 
any individual patient in this study.
When looking at the number of individual patients who had 
specific bacteria cultured at any stage there were no significant 
Table 2. Characteristics of all samples collected
Specimens Total HIV+ HIV–
p-value, 
HIV+ v. HIV–
Number of samples per patient, n (%) N=66 patients N=52 patients N=14 patients
1 33 (50.0) 28 (53.8) 5 (36) 0.654
2 17 (25.6) 13 (25) 4 (28.5)
3 6 (9.1) 4 (7.7) 2 (14.3)
4 5 (7.6) 3 (5.7) 2 (14.3)
5 2 (3.0) 2 (3.8) 0 (0)
6 2 (3.0) 1 (1.9) 1 (7.1)
7 1 (1.5) 1 (1.9) 0 (0)
Types of samples, n (%) N=134 samples N=101 samples N=33 samples
Expectorated and induced sputum 109 (81.3) 91 (90.1) 18 (54.5) <0.005
BAL and TA 25 (18.7) 10 (9.9) 15 (45.5)
Number of bacteria cultured per sample, n (%) N=134 samples N=101 samples N=33 samples
0 21 (15.7) 17 (16.8) 4 (12.1) 0.268
1 51 (38.1) 41 (40.6) 10 (30.3)
2 43 (32.1) 28 (27.7) 15 (45.5)
3 16 (11.9) 12 (11.9) 4 (12.1)
4 3 (2.2) 3 (3.0) 0 (0)
Culture density of individual bacterial colonies  
(CFU on inoculum)
N=220 colonies N=164 colonies N=56 colonies
<10 5 (2.3) 5 (3.0) 0 (0) 0.387
10 - 99 46 (20.9) 33 (20.1) 13 (23.2)
≥100 169 (76.8) 126 (76.8) 43 (76.8)
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Fig. 1. Types and percentages of bacteria cultured in airway samples. 
(*Difference is not statistically significant when the denominator is patients 
and not samples. HIV+ = HIV-infected; HIV– = HIV-uninfected.)
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differences between HIV-infected and uninfected patients for 
any of the main bacteria cultured (H. influenzae, S. pneumoniae, 
M.  catarrhalis, S. aureus, H. influenzae, Pseudomonas species and 
Klebsi ella species).
Discussion
The objective of this study was to determine whether there are 
differences in the number and type of bacteria cultured from the 
airways of HIV-infected and uninfected children.
The majority of patients with bronchiectasis in our study were 
HIV-infected, with active disease as shown by low CD4 counts 
and high viral loads. The most common bacteria cultured from 
their airways were H. influenzae, S. pneumoniae, M. catarrhalis and 
S.  aureus. When the bacteria cultured from the airways of HIV-
infected and uninfected children were compared, there were no 
differences in the number of bacterial species cultured per airway 
sample or the type of bacteria cultured.
In this study, over three-quarters (84.3%) of specimens had at 
least one bacterium cultured, with 46.2% culturing two or more 
types of bacteria. The high rate of positive samples is similar to most 
reports from countries with a low HIV incidence,[11-13] in contrast 
to Karadag et al.,[14] who isolated bacteria in only 46.9% of patients 
with bronchiectasis. The reason for this difference is not clear, but it 
could be related to the age at presentation of the patients, the severity 
of the bronchiectasis and the fact that the majority of our patients 
were HIV-infected, though we did not find differences in type and 
number of bacteria cultured between HIV-infected and uninfected 
patients. The mean (SD) age of the patients in the Turkish cohort was 
7.4 (3.7) years at presentation, while the mean age of our patients was 
9.7 (3.3) years. This would allow more time for untreated patients 
to acquire more acute infective exacerbations and possibly to be 
colonised by a larger number of bacterial species. Ferrand et al.[9] 
reported on a cohort of adolescents with HIV-associated lung disease 
and reported positive bacterial cultures in only 33% of their patients. 
The low rate of positive cultures in their cohort is probably because 
while all the children in their study had HIV-associated chronic lung 
disease, only 43% had bronchiectasis, whereas all the patients in 
our study had bronchiectasis. Masekela et al.,[10] in a study from SA, 
reported a positive culture rate of 65% when cumulative samples over 
a 1-year period were included.
H. influenzae was the most common bacterium reported in 
all studies, with a frequency ranging between 31% and 68%; and 
the frequency in our study was 36.0%. The majority of studies 
have reported similar results in terms of the most common 
bacteria cultured, namely H. influenzae followed by S. pneumoniae, 
M. catarrhalis and S. aureus.[12,15] Other studies have reported 
common bacteria that vary slightly from this study, with Karadag 
et al.[14] and Li et al.[13] reporting, in order of declining frequency, 
H. influenzae, S. pneumoniae, S. aureus and P. aeruginosa. The bac-
teria reported by these authors are similar to those in our study, 
except for a higher frequency of P. aeruginosa in their cohorts. The 
reason for this finding is not clear, but it was reported by Kapur et 
al.[11] that the presence of P. aeruginosa colonisation of the airways 
of the non-CF child with bronchiectasis could signal the presence 
of a serious underlying co-morbidity. Indeed, the only case of 
P. aeruginosa in the airway of a child without CF found by Edwards 
et al.[16] was in a patient with a tracheostomy.
Masekela et al.[10] reported that the most commonly cultured 
bacteria in samples from children who were HIV-infected and had 
bronchiectasis were H. influenzae (30%) and H. parainfluenzae (21%), 
Table 3. Types and numbers of bacteria cultured in all samples according to HIV status
Bacteria All (N=197) HIV+ (N=145) HIV–  (N=52)
p-value,  
HIV+ v. HIV–
Gram-positive bacteria 55 (27.9) 38 (26.2) 17 (32.7) 0.236
Streptococci 33 (16.8) 22 (15.2) 11 (21.2) 0.316
S. pneumoniae 25 (12.7) 18 (12.4) 7 (13.5) 0.508
Other streptococci* 8 (4.1) 4 (2.7) 4 (7.7) 0.130
Staphylococci 22 (11.2) 16 (11.0) 6 (11.5) 0.597
Methicillin-sensitive S. aureus 14 (7.1) 11 (7.6) 3 (5.8) 0.406
Methicillin-resistant S. aureus 7 (3.6) 5 (3.4) 2 (3.8) 0.596
CNS 1 (0.5) 0 (0) 1 (1.9) §
Gram-negative bacteria 142 (72.1) 107 (73.8) 35 (67.3) 0.236
H. influenzae 71 (36.0) 55 (37.9) 16 (30.7) 0.226
M. catarrhalis 22 (11.2) 18 (12.4) 4 (7.7) 0.301
Pseudomonas† 13 (6.6) 4 (2.8) 9 (17.3) 0.001
Klebsiella spp. (all ESBL) 11 (5.6) 9 (6.2) 2 (3.8) 0.408
H. parainfluenzae 10 (5.1) 9 (6.2) 1 (1.9 0.207
E. coli (all ESBL) 6 (3.0) 6 (4.1) 0 (0) 0.155
Enterobacter spp. 4 (2.0) 3 (2.1) 1 (1.9) 0.715
Other Gram-negative bacteria‡ 5 (2.5) 3 (2.1) 2 (3.8) 0.397
All ESBL organisms 17 (8.6) 15 (10.3) 2 (3.8) 0.12
HIV+ = HIV-infected; HIV– = HIV-uninfected; CNS = coagulase-negative staphylococci; ESBL = extended-spectrum beta-lactamase producing.
*S. viridans, S. pyogenes and group C + G streptococci.
†P. aeruginosa + P. fluorescens.
‡Morganella morganii, P. mirabilis, Pantoea and Neisseria spp.
§Numbers in this row are small, so p-value not applicable.
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with M. catarrhalis following at 4% and no S. pneumoniae, S. aureus 
or P. aeruginosa reaching a frequency of >2%. These findings are very 
different to ours, with a much higher frequency of H. parainfluenzae 
and much lower frequencies of all the other bacteria. The reason for 
this difference is unclear. The findings of Ferrand et al.[9] were similar 
to ours, but with a lower frequency of S. pneumoniae and a higher 
frequency of S. aureus. The numbers in the Ferrand study were very 
small and therefore difficult to interpret.
Study limitations
There are a number of limitations to this study. Firstly, it was a 
retrospective observational study, potentially allowing for selection 
and information bias. It is possible that not all patients with 
bronchiectasis were referred to the paediatric pulmonology service. 
Secondly, the number of HIV-uninfected patients was quite small 
compared with the number of HIV-infected patients, and owing 
to the retrospective nature of the study they were not perfectly 
matched with the HIV-infected patients, especially with regard 
to age. There is also current evidence that the lung microbiome 
in HIV-infected patients with low CD4 counts is different to that 
in patients with preserved CD4 counts, and that even after highly 
active antiretroviral therapy these changes are not fully reversed.[17] 
In theory, this could also have influenced the results of this study. 
More HIV-uninfected than infected patients had BAL samples taken, 
which may have influenced the outcome of the culture results. HIV-
uninfected children are more likely to have undergone bronchoscopy 
in the course of work-up for the cause of their bronchiectasis, while 
in HIV-infected children the cause of the bronchiectasis is usually 
known to be recurrent and severe chest infections. BAL samples 
are collected from a specific area in the lung, usually determined as 
the most representative area of disease on radiological assessment, 
while in theory an expectorated sample is more representative 
of the entire lung. This may also have influenced the findings on 
culture of the samples. Another limitation is that it was not often 
recorded whether samples were collected during acute infective 
exacerbations or routine clinic follow-up visits. There is a possibility 
that sputum microflora could differ between routine collections and 
times of acute infective exacerbations, although this has not been 
shown in previous studies, and the recommendation is still to treat 
acute infective exacerbations with antibiotics that are guided by the 
bacteria cultured during healthy periods.[18]
Although there were fewer HIV-uninfected than HIV-infected 
patients, a strength of this study is that we made a direct comparison 
of numbers and types of bacteria grown in the samples from 
airways of HIV-infected and uninfected patients, which has not been 
reported in previous studies.
Conclusion
Antibiotics prescribed for an acute exacerbation in children with 
non-CF bronchiectasis, regardless of HIV status, should be tar-
geted against Gram-positive and Gram-negative bacteria including 
H. influ enzae, S. pneumoniae and S. aureus.
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